Cargando…

Microvesicles from cerebrospinal fluid of patients with Alzheimer’s disease display reduced concentrations of tau and APP protein

Microvesicles are small membranous particles generated during cellular activation or stress. The analysis of the content and the surface of microvesicles allow conclusions about the cells they are originating from and the underlying pathology. Therefore, CSF microvesicles have been suggested to be p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spitzer, Philipp, Mulzer, Linda-Marie, Oberstein, Timo Jan, Munoz, Luis Enrique, Lewczuk, Piotr, Kornhuber, Johannes, Herrmann, Martin, Maler, Juan Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506501/ https://www.ncbi.nlm.nih.gov/pubmed/31068645 http://dx.doi.org/10.1038/s41598-019-43607-7

Ejemplares similares

Cerebrospinal Fluid of Patients With Alzheimer’s Disease Contains Increased Percentages of Synaptophysin-Bearing Microvesicles
por: Utz, Janine, et al.
Publicado: (2021)

Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease
por: Spitzer, Philipp, et al.
Publicado: (2019)

Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines
por: Spitzer, Philipp, et al.
Publicado: (2020)

The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes
por: Oberstein, Timo Jan, et al.
Publicado: (2021)

Imbalance of Circulating T(h)17 and Regulatory T Cells in Alzheimer’s Disease: A Case Control Study
por: Oberstein, Timo Jan, et al.
Publicado: (2018)

Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy
por: Sembill, Jochen A, et al.
Publicado: (2023)

Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy
por: Oberstein, Timo Jan, et al.
Publicado: (2022)

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
por: Hellwig, Konstantin, et al.
Publicado: (2015)

A Specific Reduction in Aβ(1−42) vs. a Universal Loss of Aβ Peptides in CSF Differentiates Alzheimer's Disease From Meningitis and Multiple Sclerosis
por: Spitzer, Philipp, et al.
Publicado: (2018)

Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ERlangen Score
por: Utz, Janine, et al.
Publicado: (2023)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

Phagocytosis and LPS alter the maturation state of β-amyloid precursor protein and induce different Aβ peptide release signatures in human mononuclear phagocytes
por: Spitzer, Philipp, et al.
Publicado: (2010)

Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer’s Disease Pathology, and Cognitive Decline
por: Ouanes, Sami, et al.
Publicado: (2022)

PASSED: Brain atrophy in non-demented individuals in a long-term longitudinal study from two independent cohorts
por: Haas, Anna-Lena, et al.
Publicado: (2023)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Characterization of Acid Sphingomyelinase Activity in Human Cerebrospinal Fluid
por: Mühle, Christiane, et al.
Publicado: (2013)

Clinical significance of fluid biomarkers in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2020)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

Amyloidogenic amyloid-β-peptide variants induce microbial agglutination and exert antimicrobial activity
por: Spitzer, Philipp, et al.
Publicado: (2016)

Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms
por: Winkel, Izabela, et al.
Publicado: (2021)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Digit Ratio (2D:4D) Is Not Associated with Alzheimer’s Disease in the Elderly
por: Siegmann, Eva-Maria, et al.
Publicado: (2023)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network
por: Benson, Gloria S., et al.
Publicado: (2022)

CD133-Positive Membrane Particles in Cerebrospinal Fluid of Patients with Inflammatory and Degenerative Neurological Diseases
por: Bobinger, Tobias, et al.
Publicado: (2017)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Quantitative proteomic characterization of microvesicles/exosomes from the cerebrospinal fluid of patients with acute bilirubin encephalopathy
por: Tan, Ning, et al.
Publicado: (2020)

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment
por: Schedin‐Weiss, Sophia, et al.
Publicado: (2020)

Cerebrospinal Fluid-Derived Microvesicles From Sleeping Sickness Patients Alter Protein Expression in Human Astrocytes
por: Dozio, Vito, et al.
Publicado: (2019)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2019)

Tau protein as a possible marker of cerebrospinal fluid leakage in cerebrospinal fluid rhinorrhoea: A pilot study
por: Oudart, Jean-Baptiste, et al.
Publicado: (2017)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

Spot quantification in two dimensional gel electrophoresis image analysis: comparison of different approaches and presentation of a novel compound fitting algorithm
por: Brauner, Jan M, et al.
Publicado: (2014)

Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice
por: Skachokova, Zhiva, et al.
Publicado: (2019)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fgolgq6ojhu0g7ak28boqdvlbo